drugset / Trial / NCT01837082
Iron in Congestive Heart Failure
Phase 3
Terminated
18 enrolled
University of Ulm
RWTH Aachen University · collabUniversitätsklinikum Hamburg-Eppendorf · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The hypothesis to be tested is whether treatment with intravenous iron (ferric carboxymaltose) will improve left-ventricular ejection fraction in patients with heart failure and iron deficiency as determined by cardiac magnetic resonance imaging.
Timeline
- Start
- 2013-04
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ferric carboxymaltose | Other / unclassified | — | Intravenous |